Jon Mcclelland Lockard

Array ( [id] => 16222769 [patent_doc_number] => 20200247885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => P2X4 ANTIBODIES & USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/840910 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25457 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16840910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20343154 [patent_doc_number] => 12466876 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-11 [patent_title] => Testis development related protein antibodies [patent_app_type] => utility [patent_app_number] => 17/599454 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 21 [patent_no_of_words] => 13538 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17599454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20116045 [patent_doc_number] => 12365734 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => Anti-alpha beta TCR binding polypeptides with reduced fragmentation [patent_app_type] => utility [patent_app_number] => 17/441028 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 14 [patent_no_of_words] => 12451 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17441028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17640700 [patent_doc_number] => 20220168438 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => COMBINATION OF ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND PARP INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/442608 [patent_app_country] => US [patent_app_date] => 2020-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51230 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17442608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17672728 [patent_doc_number] => 20220185895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => METHODS OF REDUCING LARGE GRANULAR LYMPHOCYTE AND NATURAL KILLER CELL LEVELS [patent_app_type] => utility [patent_app_number] => 17/599481 [patent_app_country] => US [patent_app_date] => 2020-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23831 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17599481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17611584 [patent_doc_number] => 20220153863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => PRAME BINDING MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/438653 [patent_app_country] => US [patent_app_date] => 2020-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15683 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17438653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20264175 [patent_doc_number] => 12435151 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Anti-TNFR2 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/434340 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 109 [patent_no_of_words] => 37441 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17434340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17593567 [patent_doc_number] => 20220143140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => ANTI-CD6 ANTIBODY COMPOSITIONS AND METHODS FOR TREATING LUPUS [patent_app_type] => utility [patent_app_number] => 17/434247 [patent_app_country] => US [patent_app_date] => 2020-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24659 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17434247 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16253531 [patent_doc_number] => 20200262905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => DUAL PDGF/VEGF ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/795450 [patent_app_country] => US [patent_app_date] => 2020-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40476 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16795450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628744 [patent_doc_number] => 20210047397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => METHODS FOR TREATING VISCERAL PAIN BY ADMINISTERING ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE [patent_app_type] => utility [patent_app_number] => 16/791406 [patent_app_country] => US [patent_app_date] => 2020-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16791406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19738340 [patent_doc_number] => 12215158 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => CD1a antibody-expressing CAR T-cells for the treatment of CD1a-positive cancer [patent_app_type] => utility [patent_app_number] => 17/430705 [patent_app_country] => US [patent_app_date] => 2020-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 12 [patent_no_of_words] => 13986 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17430705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595344 [patent_doc_number] => 20220144917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => STABILIZED EXTRACELLULAR DOMAIN OF CD19 [patent_app_type] => utility [patent_app_number] => 17/435370 [patent_app_country] => US [patent_app_date] => 2020-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21104 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17435370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17334642 [patent_doc_number] => 20220000973 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => Targeting CD24-Siglec Interactions for the Treatment and Prevention of Nonalcoholic Steatohepatitis [patent_app_type] => utility [patent_app_number] => 17/428769 [patent_app_country] => US [patent_app_date] => 2020-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17428769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17975552 [patent_doc_number] => 11492400 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-08 [patent_title] => Antibodies to L-type voltage gated channels and related methods [patent_app_type] => utility [patent_app_number] => 16/751951 [patent_app_country] => US [patent_app_date] => 2020-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 10 [patent_no_of_words] => 27019 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16751951 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20302450 [patent_doc_number] => 12448428 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => HLA class II-restricted t cell receptors against RAS with G12R mutation [patent_app_type] => utility [patent_app_number] => 17/424591 [patent_app_country] => US [patent_app_date] => 2020-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 15180 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17424591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533637 [patent_doc_number] => 20220112246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => CONFORMATIONAL EPITOPE OF HEPATITIS B SURFACE ANTIGEN AND ANTIBODY BINDING SPECIFICALLY THERETO [patent_app_type] => utility [patent_app_number] => 17/417603 [patent_app_country] => US [patent_app_date] => 2020-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17417603 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443821 [patent_doc_number] => 20220064326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => HIGHLY MODULAR BIEPITOPIC AND BISPECIFIC CAR-T CELLS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/420251 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17420251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16175565 [patent_doc_number] => 20200222533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => Methods Of Treatment Of Keloid Using An Anti-VEGF Agent [patent_app_type] => utility [patent_app_number] => 16/740143 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8648 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16740143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15831929 [patent_doc_number] => 20200131246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION [patent_app_type] => utility [patent_app_number] => 16/739559 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4798 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16739559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16296299 [patent_doc_number] => 20200282022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES [patent_app_type] => utility [patent_app_number] => 16/720970 [patent_app_country] => US [patent_app_date] => 2019-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64680 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16720970 [rel_patent_id] =>[rel_patent_doc_number] =>)